TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A South Asian physician says she was screened for diabetes at a BMI of 26.5 under guidance recognizing risk at lower weights, but could not qualify for a GLP-1 drug under the BMI thresholds commonly used for coverage. Her MedPage Today commentary argues that screening and prescribing standards do not account for Asian body composition in the same way. The account describes a policy mismatch; it does not establish that every insurer uses identical rules or that a specific coverage decision is universal.
A South Asian physician with a BMI of 26.5 says she was screened for diabetes under guidance that recognizes elevated risk at lower BMI in Asian Americans, but was denied a GLP-1 medication because she did not meet the weight-based eligibility thresholds used in her case. In a MedPage Today commentary published October 31, Hamayle Saeed, MD, argues that the gap exposes a mismatch between diabetes-risk guidance and the BMI cutoffs commonly used by insurers for weight-loss drug coverage.
Saeed writes that her doctor began diabetes screening in line with American Diabetes Association guidance for Asian Americans, which uses a BMI of 23 as a screening threshold. She says she asked about a GLP-1 receptor agonist but was not eligible: at BMI 26.5, she had neither diabetes nor a BMI high enough to meet the criteria applied to her. The thresholds she describes are BMI 30, or 27 with a weight-related condition.
The account is a physician’s personal experience and argument, not a survey of insurer decisions. Saeed says the same BMI prompted screening but did not qualify her for medication. She also notes that coverage for weight-loss GLP-1s has been reduced in some public programs: California’s Medi-Cal dropped coverage in January, she writes, and Massachusetts’ MassHealth followed in July. The commentary does not detail every plan’s policy or exceptions.
Saeed cites research on Asian-specific risk and treatment. A study of nearly 1.5 million adults in England estimated that South Asian adults reached the diabetes risk associated with BMI 30 among white adults at a BMI of 23.9; the corresponding estimate for Chinese adults was 26.9. She also cites the 2025 STEP 11 trial, conducted in South Korea and Thailand, in which participants with obesity by local criteria received semaglutide or placebo. These findings inform her case for revisiting access rules, but do not by themselves establish coverage eligibility or prove that results apply to every patient group.
How BMI Rules Shape Drug Access
The issue affects how patients are identified as at risk and whether they can access treatment. If screening thresholds recognize elevated diabetes risk at lower BMI for Asian Americans while coverage rules rely on higher cutoffs, some patients may be flagged for monitoring but remain ineligible for weight-loss medication. Screening and treatment access serve different purposes, but the mismatch can leave patients and clinicians without a clear path from risk recognition to covered care.
The disagreement also has policy consequences as public coverage contracts. Saeed argues that patients near eligibility limits are more exposed when benefits are narrowed. The rules can shape who receives treatment, while trial enrollment criteria and drug labels influence what evidence and indications are available to payers. Coverage decisions remain plan-specific; the commentary does not show that all Asian patients are denied or that all insurers apply a single threshold.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
Garmin Venu® 3 Premium Fitness Smartwatch 45mm Black
As an affiliate, we earn on qualifying purchases.
Why Asian-Specific BMI Cutoffs Matter
BMI is a screening measure based on height and weight, not a direct measurement of body fat distribution. Saeed points to guidance from the World Health Organization that set lower action points for Asian populations, at BMI 23 and 27.5, and to the ADA’s use of BMI 23 for diabetes screening in Asian Americans. The commentary says Asian adults can develop type 2 diabetes and cardiovascular disease at lower BMI than white adults, in part because of differences in visceral fat and muscle mass.
Those risk thresholds do not automatically determine a drug’s approved use or insurer coverage. Saeed says U.S. eligibility forms commonly retain BMI cutoffs of 30, or 27 with a weight-related condition, even as the 2026 labels for Wegovy and Zepbound describe indications using the terms “obesity” and “overweight” without stating a number in the indication wording. She argues that trial criteria and payer forms continue to shape access. The article excerpt does not provide the full label language or establish how every insurer interprets it.
Saeed also cites a 2026 analysis of 352 GLP-1 trials, reporting that BMI cutoffs reduced eligibility among Asian participants more than other cited criteria. In the analysis as described, a BMI cutoff of 30 made 13.5% of Asian American adults and 7.2% of Korean adults eligible, compared with 41.5% of non-Asian American adults. These figures refer to modeled eligibility under the trial criterion, not actual prescribing or insurance approval.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5.”
— Hamayle Saeed, MD, in MedPage Today
Coverage Rules Still Vary
The commentary describes one physician’s experience and summarizes selected guidelines and studies. It does not identify the insurer or plan involved in Saeed’s denial, provide the prior-authorization form, or explain whether other clinical factors or appeal options were considered. The exact reason for her decision is not independently documented in the supplied material.
It is also unclear how widely insurers have adopted the 2026 label wording Saeed references, or whether plans use ethnicity-adjusted definitions when reviewing requests. The cited research does not establish that lower BMI thresholds would produce the same benefits, risks, or cost-effectiveness for every patient. Nor does the source establish that all Asian American patients face the same clinical risk or coverage outcome.
Whether Payers Revise Their Criteria
The next developments to watch are whether insurers revise prior-authorization rules to reflect updated clinical guidance and whether professional groups or regulators clarify how “obesity” in drug indications should be assessed across populations. Saeed’s commentary calls for coverage policies to account for population-specific risk; the supplied report does not announce a pending policy change or a payer response.
Patients and clinicians will also need to distinguish diabetes screening from eligibility for a weight-loss medicine. The criteria can differ by diagnosis, drug, plan and individual medical history. Any change in access would depend on decisions by insurers and public programs, alongside evidence considered by clinical and regulatory bodies.
Key Questions
Why was the physician screened at BMI 26.5?
She says her doctor followed ADA guidance using BMI 23 for diabetes screening in Asian Americans. Screening identifies people who may need testing; it does not mean a person has diabetes or automatically qualifies for medication.
What GLP-1 eligibility thresholds did she encounter?
Saeed says the criteria applied in her case required a BMI of 30, or 27 with a weight-related condition. Requirements can vary by medication, insurer and plan.
Does the report show that all Asian patients are denied GLP-1s?
No. It describes one physician’s experience and argues that common BMI-based rules may disadvantage some Asian patients. It does not establish that every insurer uses the same criteria or that every patient receives the same decision.
Do lower diabetes-screening thresholds change insurance coverage?
Not automatically. Screening guidance and coverage criteria are separate rules. The commentary argues that their differing thresholds can create an access gap, but does not report a universal coverage policy change.
What evidence does the commentary cite?
It cites an England study estimating diabetes-risk equivalence at lower BMI for South Asian and Chinese adults, a 2025 semaglutide trial in South Korea and Thailand, and a 2026 analysis of GLP-1 trial eligibility. These findings do not, by themselves, determine an individual’s treatment or insurance coverage.
Source: medpagetoday.com
